A randomised phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumours

被引：0
|
作者：
Hyung-Don Kim
Changhoon Yoo
Min-Hee Ryu
Yoon-Koo Kang
机构：
[1] University of Ulsan College of Medicine,Department of Oncology, Asan Medical Center
来源：
British Journal of Cancer | 2023年 / 129卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：275 / 282
页数：7
相关论文
共 50 条
  • [31] A phase IIII study of AMN107, a novel aminopyrimidine inhibitor of bcr-abl, on a continuous daily dosing schedule in adult patients (pts) with imatinib-resistant advanced phase chronic myeloid leukemia (CML) or relapsed/refractory Philadelphia chromosome (Ph plus ) acute llymphocytic leukemia (ALL).
    Giles, F
    Kantarjian, H
    Wassmann, B
    Cortes, J
    O'Brien, S
    Tanaka, C
    Rae, P
    Mietlowski, W
    Romano, A
    Alland, L
    Dugan, M
    Albitar, M
    Ottmann, O
    BLOOD, 2004, 104 (11) : 10A - 11A
  • [32] A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours
    F A L M Eskens
    C H Mom
    A S T Planting
    J A Gietema
    A Amelsberg
    H Huisman
    L van Doorn
    H Burger
    P Stopfer
    J Verweij
    E G E de Vries
    British Journal of Cancer, 2008, 98 : 80 - 85
  • [33] A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor I (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours
    Eskens, Falm
    Mom, C. H.
    Planting, A. S. T.
    Gietema, J. A.
    Amelsberg, A.
    Huisman, H.
    van Doorn, L.
    Burger, H.
    Stopfer, P.
    Verweij, J.
    de Vries, Ege
    BRITISH JOURNAL OF CANCER, 2008, 98 (01) : 80 - 85
  • [34] Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Patients with Relapsing Multiple Sclerosis over 48 Weeks: a Randomised, Placebo-controlled, Phase 2 Study
    Bojanowski, J.
    Montalban, X.
    Arnold, D. L.
    Weber, M. S.
    Staikov, I.
    Piasecka-Stryczynska, K.
    Martin, E. C.
    Syed, S.
    Dangond, F.
    Wolinsky, J. S.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (09) : NP69 - NP70
  • [35] Primary analysis of a randomised, placebo-controlled, phase 2 study of the Bruton's tyrosine kinase inhibitor evobrutinib (M2951) in patients with relapsing multiple sclerosis
    Montalban, X.
    Arnold, D. L.
    Weber, M. S.
    Staikov, I.
    Piasecka-Stryczynska, K.
    Willmer, J.
    Martin, E.
    Dangond, F.
    Wolinsky, J. S.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 984 - 985
  • [36] Correlation Analyses of Imetelstat Exposure with Pharmacodynamic Effect, Efficacy and Safety in a Phase 2 Study in Patients with Higher-Risk Myelofibrosis Refractory to Janus Kinase Inhibitor Identified an Optimal Dosing Regimen for Phase 3 Study
    Mascarenhas, John
    Komrokji, Rami S.
    Cavo, Michele
    Martino, Bruno
    Niederwieser, Dietger
    Reiter, Andreas
    Scott, Bart L.
    Baer, Maria R.
    Hoffman, Ronald
    Odenike, Olatoyosi
    Sherman, Laurie
    Dougherty, Souria
    Feller, Faye
    Sun, Libo
    Wan, Ying
    Rizo, Aleksandra
    Huang, Fei
    Kiladjian, Jean-Jacques
    BLOOD, 2020, 136
  • [37] Phase I dose escalation study of continuous oral dosing of OSI-906, an insulin like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor, in patients with advanced solid tumors
    Lindsay, C. R.
    Chan, E.
    Evans, T. R.
    Campbell, S.
    Bell, P.
    Stephens, A. W.
    Franke, A.
    Poondru, S.
    Rothenberg, M. L.
    Puzanov, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [38] Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study
    Chari, Ajai
    Chhabra, Saurabh
    Usmani, Saad
    Larson, Sarah
    Niesvizky, Ruben
    Matous, Jeffrey
    Gasparetto, Cristina
    Holkova, Beata
    Lunning, Matthew
    Valent, Jason
    Anderson, Larry D., Jr.
    Karanes, Chatchada
    Kwei, Long
    Chang, Lipo
    Graef, Thorsten
    Bilotti, Elizabeth
    McDonagh, Kevin
    BLOOD, 2015, 126 (23)
  • [39] Phase 2 Study of Tirabrutinib (ONO/GS-4059), a Second-Generation Bruton's Tyrosine Kinase Inhibitor, Monotherapy in Patients with Treatment-Naive or Relapsed/Refractory Waldenstrom Macroglobulinemia
    Munakata, Wataru
    Sekiguchi, Naohiro
    Shinya, Rai
    Suzuki, Kenshi
    Handa, Hiroshi
    Shibayama, Hirohiko
    Endo, Tomoyuki
    Terui, Yasuhito
    Iwaki, Noriko
    Fukuhara, Noriko
    Tatetsu, Hiro
    Iida, Shinsuke
    Ishikawa, Takayuki
    Shiibashi, Ryota
    Izutsu, Koji
    BLOOD, 2019, 134
  • [40] Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours
    Soria, Jean-Charles
    Baselga, Jose
    Hanna, Nasser
    Laurie, Scott A.
    Bahleda, Rastislav
    Felip, Enriqueta
    Calvo, Emiliano
    Armand, Jean-Pierre
    Shepherd, Frances A.
    Harbison, Christopher T.
    Berman, David
    Park, Jong-Soon
    Zhang, Steven
    Vakkalagadda, Blisse
    Kurland, John F.
    Pathak, Ashutosh K.
    Herbst, Roy S.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (08) : 1815 - 1824
12345